乌苯美司联合放化疗对晚期肺癌免疫功能的影响  

Effect of Ubenimex with Radiotherapy or Chemotherapy on the Immune Function of Advanced Lung Cancer

作　　者：雷培森[1] 王建忠[1] 师瑞[1] 李昊[1] 阿明[1] 毛成涛[1] 杨甲强[1] 花华[1] 张红军[1] 

机构地区：[1]中国人民解放军第四五一医院肿瘤科,陕西西安710054

出　　处：《现代生物医学进展》2017年第22期4307-4310,共4页Progress in Modern Biomedicine

摘　　要：目的:评价乌苯美司联合放化疗对晚期非小细胞肺癌(NSCLC)患者免疫功能的影响。方法:选择2014年1月至2016年1月来我院进行初治的NSCLC患者78例,按随机数字表法分为对照组和实验组各39例。对照组进行常规放化疗,实验组在常规放化疗的基础上加服乌苯美司进行治疗。观察并比较两组患者治疗前后免疫功能的情况。结果:实验组治疗后血清可溶性白细胞介素-2受体(sIL-2R)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子(TNF-α)水平与治疗前相比有所下降,且实验组显著低于对照组(P<0.05)。实验组治疗后外周血中T细胞亚群(CD3^+、CD4^+)和NK细胞所占比例及CD4^+/CD8^+的比值与治疗前相比有所升高,且实验组高于对照组(P<0.05);CD8^+所占比例有所下降,且实验组低于对照组,差异均具有统计学意义(P<0.05)。结论:通过检测外周血中T细胞亚群、NK细胞含量和血清sIL-2R、IL-6、IL-8、TNF-α水平,可以反映患者的免疫状态。乌苯美司联合放化疗能够有效提高晚期NSCLC患者的免疫功能,可作为化疗的辅助性用药。Objective： To evaluate the effect of Ubenimex on the immune function of patients with advanced non-small cell lung cancer （NSCLC）. Methods＂ 78 patients with NSCLC who were in our hospital from January 2014 to January 2016 were selected, they were divided into control group and experimental group according to the random number table method, 39 cases in cash group, the control group was received conventional radiotherapy and chemotherapy, the experimental group was treated with Ubenimex on the basis of conventional radiotherapy and chemotherapy. The immune function of the two groups before and after treatment should be observed and compared. Results： Compared with before treatment, the levels of serum soluble interleukin -2 receptor （slL-2R）, interleukin -6 （1L-6）, interleukin -8 （IL-8） and tumor necrosis factor （TNF-α） were decreased in the experimental group after treatment, and the experimental group was lower than that of the control group, the difference was statistically significant （P〈0.05）. The proportion ofT cell subsets （CD3＋, CD4＋） and NK cells in peripheral blood and the ratio of CD4＋/CD8＋ of the experimental group were increased compared with before treatment, and the experimental group was higher than that in the control group （P〈0.05）. The proportion of CD8＋ has declined,and the experimental group was lower than the control group, the difference was statistically significant （P〈0.05）. Conclusion： The T cell subsets, NK cell content in peripheral blood and the levels of slL-2R, IL-6, IL-8, TNF-α in serum can reflect the immune status of the patients. Ubenimex combined with radiotherapy and chemotherapy can effectively improve the immune function of patients with advanced NSCLC, can be used as adjuvant medicine.

关 键 词：乌苯美司 放化疗 非小细胞肺癌 免疫功能 

分 类 号：R734.2[医药卫生—肿瘤]